Article | Published:

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry


Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).

  2. 2.

    Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857–866 (2015).

  3. 3.

    Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339–1342 (2016).

  4. 4.

    Geisbert, T. W. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163, 2347–2370 (2003).

  5. 5.

    Bosio, C. M. et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188, 1630–1638 (2003).

  6. 6.

    Kondratowicz, A. S. et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl Acad. Sci. USA 108, 8426–8431 (2011).

  7. 7.

    Martinez, O. et al. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol. 12, 148–157 (2010).

  8. 8.

    Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. Nature 477, 340–343 (2011).

  9. 9.

    Côté, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344–348 (2011).

  10. 10.

    Moller-Tank, S. & Maury, W. Ebola virus entry: a curious and complex series of events. PLoS Pathog. 11, e1004731 (2015).

  11. 11.

    Rasmussen, A. L. Host factors in Ebola infection. Annu. Rev. Genom. Hum. Genet. 17, 333–351 (2016).

  12. 12.

    Davey, R. A. et al. Mechanisms of Filovirus entry. Curr. Top. Microbiol. Immunol. 411, 323–352 (2017).

  13. 13.

    Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6, 859–868 (2006).

  14. 14.

    Cameron, P. U. et al. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257, 383–387 (1992).

  15. 15.

    Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587–597 (2000).

  16. 16.

    Izquierdo-Useros, N. et al. Siglec-1 Is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol. 10, e1001448 (2012).

  17. 17.

    Puryear, W. B. et al. Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. PLoS Pathog. 9, e1003291 (2013).

  18. 18.

    Izquierdo-Useros, N. et al. Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. PLoS Biol. 10, e1001315 (2012).

  19. 19.

    Chan, R. et al. Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. J. Virol. 82, 11228–11238 (2008).

  20. 20.

    Kalvodova, L. et al. The lipidomes of vesicular stomatitis virus, Semliki Forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry. J. Virol. 83, 7996–8003 (2009).

  21. 21.

    Bavari, S. et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195, 593–602 (2002).

  22. 22.

    Feizpour, A. et al. Quantifying lipid contents in enveloped virus particles with plasmonic nanoparticles. Small 11, 1592–1602 (2015).

  23. 23.

    Kreuels, B. et al. A case of severe Ebola virus infection complicated by Gram-negative septicemia. N. Engl. J. Med. 371, 2394–2401 (2014).

  24. 24.

    Villinger, F. et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179, S188–S191 (1999).

  25. 25.

    Martin-Serrano, J., Perez-Caballero, D. & Bieniasz, P. D. Context-dependent effects of L domains and ubiquitination on viral budding. J. Virol. 78, 5554–5563 (2004).

  26. 26.

    Lin, G. et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77, 1337–1346 (2003).

  27. 27.

    Panchal, R. G. et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl Acad. Sci. USA 100, 15936–15941 (2003).

  28. 28.

    Peskova, M., Heger, Z., Janda, P., Adam, V. & Pekarik, V. An enzymatic assay based on luciferase Ebola virus-like particles for evaluation of virolytic activity of antimicrobial peptides. Peptides 88, 87–96 (2017).

  29. 29.

    Hartnell, A. et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97, 288–296 (2001).

  30. 30.

    Wang, J. H., Janas, A. M., Olson, W. J. & Wu, L. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J. Virol. 81, 8933–8943 (2007).

  31. 31.

    Izquierdo-Useros, N. et al. Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J. Virol. 81, 7559–7570 (2007).

  32. 32.

    Izquierdo-Useros, N. et al. Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells. Traffic 12, 1702–1713 (2011).

  33. 33.

    Yu, H. J., Reuter, M. A. & McDonald, D. HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog. 4, e1000134 (2008).

  34. 34.

    Yuan, S. et al. TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope. Protein Cell 6, 814–824 (2015).

  35. 35.

    Tscherne, D. M., Manicassamy, B. & García-Sastre, A. An enzymatic virus-like particle assay for sensitive detection of virus entry. J. Virol. Methods 163, 336–343 (2010).

  36. 36.

    Dahlmann, F. et al. Analysis of Ebola virus entry into macrophages. J. Infect. Dis. 212, S247–S257 (2015).

  37. 37.

    Martinez-Picado, J. et al. Identification of Siglec-1 null individuals infected with HIV-1. Nat. Commun. 7, 12412 (2016).

  38. 38.

    Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).

  39. 39.

    Pino, M. et al. HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. Retrovirology 12, 37 (2015).

  40. 40.

    Martinez, O. et al. Ebola virus exploits a monocyte differentiation program to promote its entry. J. Virol. 87, 3801–3814 (2013).

  41. 41.

    Rempel, H., Calosing, C., Sun, B. & Pulliam, L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS ONE 3, e1967 (2008).

  42. 42.

    Moller-Tank, S., Kondratowicz, A. S., Davey, R. A., Rennert, P. D. & Maury, W. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J. Virol. 87, 8327–8341 (2013).

  43. 43.

    Jemielity, S. et al. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 9, e1003232 (2013).

  44. 44.

    Steiniger, B., Barth, P., Herbst, B., Hartnell, A. & Crocker, P. R. The species-specific structure of microanatomical compartments in the human spleen: strongly sialoadhesin-positive macrophages occur in the perifollicular zone, but not in the marginal zone. Immunology 92, 307–316 (1997).

  45. 45.

    Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14, 1247–1255 (2008).

  46. 46.

    Cook, J. D. & Lee, J. E. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 9, e1003258 (2013).

  47. 47.

    Kaletsky, R. L., Francica, J. R., Agrawal-Gamse, C. & Bates, P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl Acad. Sci. USA 106, 2886–2891 (2009).

  48. 48.

    Derking, R. et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 11, e1004767 (2015).

  49. 49.

    Myszka, D. G. Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzym. 323, 325–340 (2000).

  50. 50.

    Ströher, U. et al. Infection and activation of monocytes by marburg and Ebola viruses. J. Virol. 75, 11025–11033 (2001).

Download references


For their excellent assistance, advice and imaging processing we thank E. Rebollo and J. Boix from the Advanced Fluorescence Microscopy Unit IBMB-PCB. We are also grateful to A. M. García-Cabrero and M. Lozano from Protein Tools at CNB for mAb purification. At HUGTiP, we thank all surgeons from the Otorhinolaryngology Department for their support, and E. Sayós Ortega and L. Pérez-Roca from the Histopathology & Electron Microscopy Platform for their outstanding sample processing and management. We thank P. Resa-Infante for critical reading of our manuscript. We thank C. Muñoz-Fontela for helpful discussions. We thank C. Galvez for PCR identification of the Siglec-1 null individual. We also thank the Microscopy Core Facility at IGTP for providing access to the Zeiss 710 confocal microscope, and the Advanced Light Microscopy Unit at the Centre for Genomic Regulation (CRG, Barcelona, Spain) for access to the Leica STED microscope. J.M.-P. and N.I.-U. are supported by the Spanish Secretariat of State of Research, Development and Innovation through grant No. SAF2016-80033-R. J.M.-P. is supported by the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA. D.P.-Z. is supported by the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund under agreement No. BES-2014-069931. J.C. is supported by Catalan Department of Health, PERIS fellowship (No. SLT006/17/00214). S.B. is supported by the Rio Hortega programme funded by the Spanish Health Institute Carlos III (No. CM17/00242). X.M.-T. is supported by the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund under agreement No. BES-2017-082900. This research was sponsored in part by Grifols.

Author information

D.P.-Z., L.K., J.M.-P. and N.I.-U. conceived and designed the experiments. M.G.-G., M.M. and L.K. generated and characterized the mAbs. D.G. contributed materials. D.P-Z, I.E., M.P., M.G.-G., M.M., S.B., J.C. and X.M.-T. performed the experiments. D.P.-Z., I.E., M.P., M.G.-G., M.M., S.B., J.C., M.F.F., V.U., L.K., J.M.-P. and N.I.-U. analysed and interpreted the data. D.P.-Z. and N.I.-U. wrote the paper. J.M.-P. and N.I.-U. performed critical revision.

Competing interests

A patent application based on this work has been filed (US 62/828,195). The authors declare no other competing interests.

Correspondence to Javier Martinez-Picado or Nuria Izquierdo-Useros.

Supplementary information

Supplementary Information

Supplementary Tables 1–4, Supplementary Figures 1–10 and Supplementary Video Legends.

Reporting Summary

Supplementary Video 1

Confocal microscopy analysis of LPS DCs. Cells were pulsed and labeled as in Fig. 2h. Videos show 3D reconstruction of the maximum intensity fluorescence built with Volocity Software.

Supplementary Video 2

Confocal microscopy analysis of LPS DCs. Cells were pulsed and labeled as in Fig. 2h. Videos show 3D reconstruction of the maximum intensity fluorescence built with Volocity Software.

Supplementary Video 3

Super-resolution microscopy analysis of the VCC from LPS DCs. Cells were pulsed and stained as in Fig. 2j. Videos show 3D reconstruction built with Imaris Software.

Supplementary Video 4

Super-resolution microscopy analysis of the VCC from LPS DCs. Cells were pulsed and stained as in Fig. 2j. Videos show 3D reconstruction built with Imaris Software.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Activation of DCs enhances Ebola viral binding and uptake via Siglec-1 recognition of gangliosides.
Fig. 2: Siglec-1 facilitates the uptake of Ebola viruses displaying envelope glycoproteins in VCCs.
Fig. 3: Ebola virus uptake by Siglec-1 facilitates cytoplasmic viral entry into activated DCs.
Fig. 4: Generation and characterization of anti-Siglec-1 mAbs.
Fig. 5: Anti-Siglec-1 mAbs inhibit HIV-1 and Ebola viral uptake.
Fig. 6: Anti-Siglec-1 mAbs block HIV-1 trans-infection and cytoplasmic Ebola entry.